Valuation: Arctic Bioscience

Market Cap 80.87M 8.39M 7.31M 6.73M 6.19M 11.68M 807M 11.95M 79.79M 31.53M 394M 31.49M 30.79M 1.36B P/E 2026 *
-3.37x
P/E 2027 * -
Enterprise Value 147M 15.23M 13.27M 12.23M 11.24M 21.21M 1.47B 21.71M 145M 57.26M 716M 57.19M 55.93M 2.46B EV / Sales 2026 *
2.53x
EV / Sales 2027 * -
Free-Float
47.75%
Yield 2026 *
-
Yield 2027 * -
1 day-7.41%
1 week-7.69%
Current month-7.41%
1 month-12.54%
3 months-7.12%
6 months-15.49%
Current year-8.54%
1 week 2.8
Extreme 2.8
3.4
1 month 2.6
Extreme 2.6
3.4
Current year 2.6
Extreme 2.6
3.67
1 year 2.6
Extreme 2.6
4.65
3 years 1.65
Extreme 1.65
16.8
5 years 1.65
Extreme 1.65
21.7
10 years 1.65
Extreme 1.65
32
Manager TitleAgeSince
Chief Executive Officer 60 2010-12-31
Chief Executive Officer 54 2022-02-28
Director of Finance/CFO 47 2022-03-31
Director TitleAgeSince
Director/Board Member 46 2020-12-31
Chairman 68 2015-11-30
Director/Board Member 55 2014-12-31
Date Insider Type Main position Quantity % Market Cap.
23-04-23Buy

Director

943,833 3.8641%
23-04-23Buy

Director

943,833 3.8641%
23-02-22Buy

Chief Technology Officer

11,500 0.0472%
Change 5-day change 1-year change 3-year change Capi.($)
-7.41%-7.69%-20.84%-71.01% 9.03M
+0.35%-6.39%+44.70%+157.34% 1,028B
-2.69%-7.57%+57.52%+54.51% 611B
+0.44%-4.14%+27.46%+79.48% 432B
+0.98%-2.74%+28.13%+21.76% 323B
-0.34%-3.79%+26.52%+43.60% 277B
+1.63%-12.52%+17.86%+21.72% 257B
+3.39%+0.95%-25.43%-37.83% 217B
+0.86%-2.66%+20.63%+57.55% 192B
+1.28%-3.42%+17.49%+70.62% 161B
Average +0.22%-4.75%+19.40%+39.77% 349.83B
Weighted average by Cap. +0.84%-5.52%+32.95%+76.70%

Financials

2026 *2027 *
Net sales 58M 6.01M 5.24M 4.83M 4.44M 8.38M 579M 8.57M 57.23M 22.61M 283M 22.58M 22.09M 973M -
Net income -24M -2.49M -2.17M -2M -1.84M -3.47M -239M -3.55M -23.68M -9.36M -117M -9.34M -9.14M -403M -
Net Debt 66M 6.84M 5.96M 5.5M 5.05M 9.53M 658M 9.75M 65.12M 25.73M 322M 25.7M 25.13M 1.11B -
Logo Arctic Bioscience
Arctic Bioscience AS is a Norway-based biotech company developing and commercializing both pharmaceutical and nutraceutical products based on the properties of herring roe oil. Arctic Bioscience’s purpose is to provide people with autoimmune disorders an effective and healthy therapy based on marine membrane lipids. The Company is developing HRO350 - a novel investigational drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. The Company's product portfolio includes, among others, Romega, which is a producer of an omega-3 dietary supplement made from herring roe in a form of a capsule, as well as herring caviar oil and herring caviar protein offered to Business-to-Business (B2B) customers. Arctic Bioscience AS has three subsidiaries Arctic Nutrition AS, Romega AS and Arctic Biopharma AS.
Employees
19
Date Price Change Volume
26-07-15 NOK 3.000 -7.41% 5,900
26-07-14 NOK 3.240 -0.31% 1,182
26-07-13 NOK 3.250 +1.88% 17,129
26-07-10 NOK 3.190 -1.85% 2,053
26-07-09 NOK 3.250 0.00% 0
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-

Annual profits - Rate of surprise